WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

ATC level alterations

Previous ATC codeATC level nameNew ATC code
J06BB16palivizumabJ06BD01
J06BB17motavizumabJ06BD02
J06BB18raxibacumabJ06BC02
J06BB21bezlotoxumabJ06BC03
J06BB22obiltoxaximabJ06BC04
L01EX16erdafitinibL01EN01
L01EX20pemigatinibL01EN02
L01XCMonoclonal antibodiesdeleted
L01XC01edrecolomabL01FX01
L01XC02rituximabL01FA01
L01XC03trastuzumabL01FD01
L01XC05gemtuzumab ozogamicinL01FX02
L01XC06cetuximabL01FE01
L01XC07bevacizumabL01FG01
L01XC08panitumumabL01FE02
L01XC09catumaxomabL01FX03
L01XC10ofatumumabL01FA02
L01XC11ipilimumabL01FX04
L01XC12brentuximab vedotinL01FX05
L01XC13pertuzumabL01FD02
L01XC14trastuzumab emtansineL01FD03
L01XC15obinutuzumabL01FA03
L01XC16dinutuximab betaL01FX06
L01XC17nivolumabL01FF01
L01XC18pembrolizumabL01FF02
L01XC19blinatumomabL01FX07
L01XC21ramucirumabL01FG02
L01XC22necitumumabL01FE03
L01XC23elotuzumabL01FX08
L01XC24daratumumabL01FC01
L01XC25mogamulizumabL01FX09
L01XC26inotuzumab ozogamicinL01FB01
L01XC27olaratumabL01FX10
L01XC28durvalumabL01FF03
L01XC29bermekimabL01FX11
L01XC31avelumabL01FF04
L01XC32atezolizumabL01FF05
L01XC33cemiplimabL01FF06
L01XC34moxetumomab pasudotoxL01FB02
L01XC35tafasitamabL01FX12
L01XC36enfortumab vedotinL01FX13
L01XC37polatuzumab vedotinL01FX14
L01XC38isatuximabL01FC02
L01XC39belantamab mafodotinL01FX15
L01XC40dostarlimabL01FF07
L01XC41trastuzumab deruxtecanL01FD04
L01XC42prolgolimabL01FF08

Last updated: 2021-11-23